Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup

Executive Summary

Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November

You may also be interested in...

Forest Memantine Shows Small But Consistent Effect In Alzheimer’s – Cmte.

Forest memantine (Namenda) has a small but consistent effect in patients with moderate to severe Alzheimer's dementia, FDA's Peripheral & Central Nervous System Drugs Advisory Committee concluded Sept. 25

QT Interval Early Negative Signal Would Lessen Burden In Later Trials

QT interval prolongation may not need to be evaluated "intensively" in late phase trials if preclinical and Phase I studies do not show a positive signal, participants in a Drug Information Association workshop generally agreed

Pfizer Geodon QT Drug Contraindication Expanded, Clarified In New Labeling

Pfizer's Geodon should not be used by patients taking drugs that have a contraindication or boxed or bolded warning about QT prolongation, a labeling revision for the antypsychotic states

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts